Work

Abstract PS5-02-30: Prolonged survival following PD-L1/PD-1 immune checkpoint inhibitor therapy after leronlimab induced PD-L1 upregulation on cancer-associated macrophage-like cells and circulating tumor cells in patients with metastatic or locally advanced triple-negative breast cancer

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-ps5-02-30

Authors: M. V. Dolezal, V. G. Abramson, N. Chittoria, S. Ehsani, R. G. Pestell, H. S. Rugo, H. Rui, D. L. Adams, J. Meidling, M. Lataillade, J. P. Lalezari

Institutions: Stanford Medicine, Stanford University, Vanderbilt University, Vanderbilt-Ingram Cancer Center, University of Utah, Huntsman Cancer Institute, University of Arizona Cancer Center, City Of Hope National Medical Center, City of Hope, Thomas Jefferson University, Creatv MicroTech (United States), CytoDyn Inc. (United States)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7130733727

Cites:

Cited by:

Related to: